ライフサイエンスコーパス: the previously described

1 The objective of this study was to conjugate the previously described (1-N-(4-aminobenzyl)-3,6,10,13,

2 gnificant improvement in agonist activity of the previously described 2-aryloctahydrophenanthrene-2,3

3 Chemical phosphorylation of the previously described 2-guanidinyl-glucose (46) affor

4 We propose naming bacteria that express the previously described 20alpha capsule structure 20A a

5 Together with the previously described 5'-deoxyadenosyl and 3-amino-3-

6 ge events around the expected sites based on the previously described 5'/3' counting rules.

7 One contains the previously described 9 bp deletion and an additional

8 While they have a poorer affinity than the previously described A chain binders, it was found t

9 In this study, we show that, despite the previously described ability of Cur1 to antagonize t

10 Furthermore, we show that the previously described ability of sigma(28) to activat

11 hermore, our data also strongly suggest that the previously described accumulation of snR30 upon Rok1

12 the corresponding succinates, in addition to the previously described acetates.

13 Similar to the previously described action of PUX1 on AtCDC48, TUG

14 M(1)R stimulation in these cells, similar to the previously described actions of M(1)R stimulation on

15 phosphorylation sites on USF1 identified as the previously described activating site threonine 153 a

16 s earlier in Adam10DeltaEC(Flv) mice than in the previously described Adam10DeltaEC mice.

17 This finding could be related to the previously described affinity of SCR for cholesterol

18 These propensities are very similar to the previously described alcohol-denatured (A-)state.

19 First, we used the previously described allo-HLA-B*44:02 cross-reactivi

20 Here, we examined the mechanism by which the previously described aminothieno pyridazine (ATPZ) s

21 In support of the previously described antagonistic relationship betwe

22 human serum was also identified and included the previously described antigen TpF1 and the hypothetic

23 es hu5B3.v3 and MRCT10.v362 that, similar to the previously described AP33 and HCV1, bind to a highly

24 ers, and a detailed comparison was made with the previously described arylimido homologues.

25 In addition to the previously described aspartase-cleavable biosensors,

26 Moreover, we confirm the previously described associations with APOE and LPA.

27 of an Ets domain-binding site, recognized by the previously described AST-1 Ets domain factor, and tw

28 TIP60 enzymatic activity described here and the previously described ATP-dependent positioning of H2

29 of three major conformations: in addition to the previously described ATP-hydrolyzing (ATPh) and ATP-

30 We combined the Delta1313 deletion with the previously described, attenuating NS2 gene deletion

31 he A2B adenosine receptor is responsible for the previously described attenuation of ALI.

32 uloma, as demonstrated by the dissolution of the previously described B-cell-macrophage unit in granu

33 oving rAAV yield by 10-fold as compared with the previously described baculovirus/rAAV production sys

34 lity of the real-time PCR assay with that of the previously described beta-d-glucan (BDG) detection a

35 allosteric protein site that is unique from the previously described binding sites of other inhibito

36 The previously described biological properties of their

37 free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxam

38 Using the previously described blockface technique, deformatio

39 e produced BrlR being impaired in binding to the previously described BrlR-activated promoters of the

40 l region of the NP that did not overlap with the previously described C-terminal NP domain involved i

41 -subunit complex, and which is distinct from the previously described C-terminal winged-helix domain.

42 nt had compound heterozygote SCO2 mutations: the previously described c.1541G>A (p.E140K) mutation an

43 d and Epithelial morphologies clustered with the previously described C1-stromal, C5-mesenchymal and

44 acterization revealed an additional role for the previously described carbon-sulfur lyase SUR1 in pro

45 Unlike the previously described CD4(+) T-cell population that i

46 ed by the CD127 phenotype in comparison with the previously described CD4(+)CD25(hi) subpopulations,

47 Here, we miniaturize and automate the previously described Cell Surface Capture (CSC) tech

48 enii ATCC 53582 and find that in addition to the previously described cellulose synthase operon, ATCC

49 ChaC2 is distinct from the previously described ChaC1, to which ChaC2 shows app

50 CFP-10 in the ESAT-6:CFP-10 complex, beyond the previously described chaperone function.

51 chitinase genes (chiC and chiD), as well as the previously described chiA and chiB.

52 were mapped, characterized and compared with the previously described chlamydial ncRNAs.

53 indicate that Wor3 is highly integrated into the previously described circuit regulating white-opaque

54 switching, which represents a refinement to the previously described CL/K pathway, fine-tunes the pr

55 nces proposed to be antisense to that coding the previously described Class I TrpRS Urzyme.

56 The model represents a simplification of the previously described coalescent with gene conversion

57 Compared to the previously described combinatorial mutant casper, th

58 Excluding the previously described common missense variant p.Pro44

59 BQCA binding pocket partially overlaps with the previously described "common" allosteric site in the

60 muscular systolic mechanism that challenges the previously described concept of "isovolumic relaxati

61 es sensorineural hearing loss in addition to the previously described conductive hearing loss.

62 Moreover, our data show that the previously described consensus sequence PXRPXR for a

63 Furthermore, we found that the previously described cortical suppression during voc

64 ndent of PSB27, but was due to a mutation in the previously described cp26 gene that we found had no

65 obacterium bovis BCG, which is distinct from the previously described CRP(Mt) regulon.

66 The previously described CsrA family member in Pseudomon

67 gly, expression of CpuDGAT1 and CvFatB1 with the previously described CvLPAT2, a 10:0-CoA-specific Cu

68 Combining the previously described D1 receptor with its putative f

69 rebrate mouse model of the EPR is similar to the previously described decerebrate rat model.

70 The first represents the previously described defect in processing recombinat

71 This reaction is similar to the previously described demethylation reactions conduct

72 similar to macropinocytosis, albeit without the previously described dependence on oncogenic-Kras si

73 After a median follow-up time of 7.6 years, the previously described difference in OS between the in

74 All of the previously described disease manifestations in HLA-B

75 as telomeric to the 16p11.2 CNV and includes the previously described "distal" 16p11.2 microdeletion.

76 DNMT3A, therefore providing a mechanism for the previously described DNMT3L activation of DNMT3A.

77 lationship between Notch expressing HSCs and the previously described Domeless expressing progenitors

78 of the families with mutations conformed to the previously described DYT6 phenotype; however, age at

79 Complex1 (PRC1)-related complex, resembling the previously described E2F6-complex, and including G9A

80 ir characteristics and binding kinetics with the previously described E2P-ouabain complex to derive s

81 In HLA-B*5703-mismatched recipients, the previously described early benefit of transmitted HL

82 this observation, the ein2 mutation rescues the previously described effects of ethylene overproduct

83 ts on GnRH-I immunoreactivity in addition to the previously described effects of reproductive state.

84 is laminin-related function is essential for the previously described effects on axon growth promotio

85 Deletion of EFM3 or of the previously described EFM2 increases sensitivity to a

86 raft components and reveal the mechanism of the previously described elevation of cAMP after cell de

87 jor replication, and mechanistically explain the previously described endosomal TLR-mediated resistan

88 into six resistotypes that were connected to the previously described enterotypes.

89 Here we demonstrate that the previously described ENU-induced nur7 mouse mutant i

90 In this study, the previously described ERCC1-XPF inhibitor 4-((6-chlor

91 a resolution of 1.92 A and the structure of the previously described ESA/Nps complex (2.42 A), it wa

92 e domain III at a point nearly equivalent to the previously described etr1-2 mutation in the other Ar

93 atoconjunctival proliferation, as well as in the previously described familial pterygoid corneal dege

94 The previously described FFI mice develop neuronal loss

95 margin revealed new features in addition to the previously described findings.

96 The previously described flaring shapes of growing micro

97 populations, or conformational sampling, of the previously described four conformations for HIV-1PR.

98 erest, five of these novel mutations, one of the previously described frequent variants (N221D), and

99 n the default mode network, closely matching the previously described frontotemporal pattern of chang

100 We combined these new reporters with the previously described Fucci system to create Fucci4,

101 anemia compared to controls, consistent with the previously described function of CD47 in normal phag

102 aptic relay in the CeA and shed new light on the previously described functions of IC and CeA through

103 This dual function of NLRX1 paralleled the previously described functions of the autophagy-rela

104 Optimization of the previously described fused azadecalin series of sele

105 TolAIII interaction is strikingly similar to the previously described g3p-TolAIII interaction.

106 lphabeta(+) gammadelta T cells differed from the previously described gammadelta T cell subsets in se

107 e candidate coverage, we investigated all of the previously described GAS candidate antigens for gene

108 ckground of the female's mate contributes to the previously described gene expression changes, we ass

109 Assessment of the previously described gene sets relative to training

110 of MAPK phosphorylation that can account for the previously described genetic interaction between the

111 The previously described gH 824L mutation blocks gH/gL f

112 The former includes the previously described Hc gene, a deficit of which is

113 Remarkably, we observed that the previously described hCD79b promoter along with its

114 tant disorder that only partly overlaps with the previously described HCLv.

115 so show that commendamide is responsible for the previously described hemolytic activity associated w

116 Our data support a role for the previously described heparan sulfate moieties in med

117 Broadening of phenotype of some of the previously described hereditary dystonias and enviro

118 218Gfs*15, p.E470X, p.R221G, c.790-1G>T, and the previously described heterozygous p.R47X.

119 ound to site I and a pair of OBD subunits in the previously described hexameric spiral structure.

120 ncreased occurrence of tremor in addition to the previously described hindlimb clasping.

121 X4-suppressive factors differ from those of the previously described HIV R5-suppressive beta chemoki

122 as a novel virulence factor, in addition to the previously described hMPV G protein.

123 Consistent with the previously described homeostatic and anti-inflammato

124 III) cofactor to give two distinct products: the previously described homogeneous Mn(III)/Fe(III)-bet

125 re determined were found to belong to one of the previously described hospital-associated clonal clus

126 In this study, we used the previously described human (h)IL10BAC transgenic mod

127 Like the previously described ibr3 mutant, which disrupts a p

128 Megaviridae share some general features with the previously described icosahedral large DNA viruses,

129 contributions from a polymorphic gene(s) in the previously described Idd7 locus on the proximal port

130 cterization of a novel compound derived from the previously described imidazobenzodiazepine SH-053-2'

131 e investigated a novel compound derived from the previously described imidazobenzodiazepine SH-053-2'

132 ptional regulatory mechanism responsible for the previously described immunomodulatory characteristic

133 We found that the previously described immunoreactive and mesenchymal

134 Accordingly, we observed that the previously described immunosuppressive neutrophil po

135 These data explain the previously described in vivo effects on bone marrow

136 phorylation of the ABD closely recapitulated the previously described in vivo phosphorylation pattern

137 compared the resulting song phenotypes with the previously described inaccurate and incomplete song

138 hat a change from an IncA-positive strain to the previously described IncA-negative phenotype may inv

139 Our findings also account for the previously described indirect regulation by NRF1 of

140 Unlike the previously described induction of APP transcription,

141 yesian Best Subset Regression (BBSR)] extend the previously described Inferelator framework, enabling

142 The previously described inhibitory effect of TWEAK on T

143 otent p53 inhibiting activity in addition to the previously described inhibitory effects of KSHV gene

144 Complementing the previously described insulin-site 1 interaction, we

145 CD133(+) cells were a subset of the previously described integrin alpha6(+)CD34(+) bulge

146 wn that these two pathways interconnect, but the previously described interactions do not fully expla

147 ared with those with quiescent RA, including the previously described interleukin-6 (IL-6), oncostati

148 heme-binding proteins that are distinct from the previously described IsdG heme monooxygenase.

149 m with reduced thermosensitivity compared to the previously described isoform.

150 ng KCNA4, KCND2, and KCND3 genes, as well as the previously described J-wave-associated KCNJ8 gene, i

151 The previously described KCNJ8-S422L mutation was not id

152 OPA formation during the first turnover, and the previously described kinetics for formation and deca

153 Indeed, we report here that the previously described lateral root development2 mutan

154 ide RD2, a rationally designed derivative of the previously described lead compound D3, which has bee

155 mpound approximately 3-fold more potent than the previously described lead.

156 s not mediated by the stringent response nor the previously described Legionella quorum-sensing pathw

157 different regions of MSP3, we observed that the previously described leucine zipper region at the C

158 Here, we found that the previously described light-signaling component HY5 a

159 arameters, this reduction was prevented when the previously-described light procedure was applied.

160 We found convincing association to the previously described locus including the FTO gene.

161 tical kinase and leucine zipper domains with the previously described long isoform DLK-1L but acts to

162 s 14 Da larger than its calculated mass with the previously described loss of the initiator methionin

163 These new features, coupled with the previously described low-cost, high efficiency, high

164 Notably, CARBs are distinct from the previously described luminal castration-resistant Nk

165 show here that REAF is a major component of the previously described Lv2 restriction.

166 e conclude that REAF is a major component of the previously described Lv2 restriction.IMPORTANCE Meas

167 FAT transcription factor, perfectly matching the previously described LXVP calcineurin-binding consen

168 uenza subtypes, such as H1; however, none of the previously described MAbs showed broadly neutralizin

169 nsors for the detection of RNA hairpins from the previously described malachite green (MG) RNA aptame

170 Here we extend the previously described mass spectrometry-based KAYAK a

171 uced an MDSC phenotype distinct from that of the previously described MDSC-inducing cytokine GM-CSF,

172 ignature encompasses all of the hallmarks of the previously described melanoma invasive signature.

173 compare the characteristics of the EIMS with the previously described membrane inlet mass spectrometr

174 nt hybrid syntheses which combine several of the previously described methods and other paths, such a

175 the amphipathic central helices observed in the previously described micelle-associated "hairpin" st

176 ue and critical function for MK signaling in the previously described MIF/CD74-induced survival pathw

177 the MIR193BHG locus, entirely distinct from the previously described miR-193b-365a tandem.

178 Here, we isolate the genes defined by the previously described miRNA action deficient (mad) mu

179 y to what might be naively expected based on the previously described misfolding mechanism, we find t

180 We replicated the previously described MNV mutational signatures assoc

181 on of structured RNA may account for some of the previously described molecular phenotypes (e.g., alt

182 mer or higher order oligomer, in contrast to the previously described monomer, in retinal rod outer s

183 These phenotypes resemble those caused by the previously described mouse thymic virus (MTV), a put

184 The previously described MRSA strain JH1 and its vancomy

185 ibitory effect on MRTF/SRF target genes than the previously described MRTF-A inhibitor CCG-203971.

186 We confirmed the dysregulation of the previously described muscle miRNAs, miR-1, miR-133,

187 IVa2-a deletion mutant virus, DeltaIVa2, and the previously described mutant virus, pm8002.

188 zebrafish rescued the trabeculation but not the previously described myelination phenotype in the pe

189 notype associated with D453G, in common with the previously described N-terminal domain mutations Q31

190 d that the isolate does not belong to any of the previously described NDV genotypes.

191 The previously described negative association of CHIP mu

192 -dependent signaling mechanism distinct from the previously described nephrin-Nck1/2 pathway necessar

193 glycemic levels and rCBF measurements within the previously described network of hypoglycemia-respons

194 Moreover, among the previously described neurons in rSC, we recorded a n

195 In contrast to the previously described neutral loss dependent ECD meth

196 pated constitutive transcription factors and the previously described NF-kappaB-responsiveness of the

197 We combined the previously described Notch1 intramembrane proteolysi

198 f estrogen receptor alpha (ERalpha) requires the previously described nuclear receptor coactivator pr

199 The previously described nuclear restorer-of-fertility a

200 e-containing particles showed DNA ordered in the previously described nucleotide-binding pocket, supp

201 in a state, which is markedly distinct from the previously described nucleotide-free, inward-facing

202 ion, and catalytic activity were determined; the previously-described obesity risk SNPs N221D (rs6232

203 We tested for deviation from the previously described occurrences of a morning peak,

204 These findings also provide a rationale for the previously described "olfactory lens," an increase i

205 al axis variants was classified according to the previously described operative ABC classification.

206 al enzyme with both a hydrolase activity and the previously described (p)ppGpp synthetase activity, a

207 In particular, the previously described p72-ATAD3B is confirmed to be i

208 Mining the previously described parasite PKG-dependent phosphop

209 ppocampal slice cultures from rat, either by the previously described PDZ ligand TAT-GESV or by the E

210 Here, we tested whether the previously described phenotypes of double mutant kea

211 The previously described phenotypes of this animal and t

212 Further, we investigate whether the previously described "pioneer" neuron that leads FBM

213 he cytoplasm subsequently, to participate in the previously described PIWI-interacting RNA (piRNA) pa

214 HIF-1alpha is a necessary signal for VAH and the previously described plasticity in glutamatergic neu

215 lation, we identified proteins that bound to the previously described point of termination for the ma

216 d substitution and a signature tag, by using the previously described pPL2 integration vector.

217 The aim of this work was to confirm the previously described presence of caprolactam in dry

218 For the previously described primary endosymbionts, one Port

219 raction and provides a clear picture for how the previously described prolyl cis/trans isomerization

220 dynamic pattern formation including not only the previously described propagating waves, but also nea

221 re rigidly folded D-loop may explain some of the previously described properties of pY53-actin, inclu

222 Using the previously described PSA substrate Ser-Ser-Lys-Leu-G

223 ly two-lon2 and deg15, a mutant defective in the previously described PTS2-processing protease (DEG15

224 ssociated protein (MAP) 1B as the antigen of the previously described Purkinje cell cytoplasmic antib

225 Optimization departed from the previously described pyrazoline 3a and focused on im

226 Here, by using the previously described Q129H mutant virus that selecti

227 mal growth factor (EGF) stimulation parallel the previously described Rac1 activation.

228 The previously described racial disparities in ICD use w

229 TP1B by TrxR1 and is therefore distinct from the previously described reactivation of end-point oxidi

230 Here, we demonstrate that the previously described regulation of centrosome organi

231 sphorylation by CDK5 is not mediated through the previously described regulation of PP1 activity by C

232 vectors that are significantly improved over the previously described replication-dependent vectors.

233 1 deletion mutants were used to reconstitute the previously described restriction phenotypes associat

234 The previously described reverse repressor TetR only fun

235 factor 1 (DMRT1) gene that is independent of the previously described risk allele (rs755383) at this

236 These studies could explain the previously described role for mu1 in influencing reo

237 Our data suggest that in addition to the previously described role of CASPR2 in mature neuron

238 Therefore, in addition to the previously described role of MCs orchestrating the e

239 functional analyses of these genes confirmed the previously described roles of some of the genes and

240 onversion can occur by two different routes: the previously described route in which PfAP2-G-expressi

241 In all of the previously described RpPat substrates, this lysine r

242 pact of the Y169G substitution together with the previously described S170N, N174T "rigid loop" subst

243 In combination with the previously described S241P mutation, we present an I

244 real melphalan injections given according to the previously described safety-enhanced technique.

245 AP form a binding site that is distinct from the previously described SAP-FcgammaRIIa binding site.

246 One of these domains is located within the previously described SARS-unique domain, and there i

247 parameter optimization of a key aryl ring of the previously described SB1518 (pacritinib), the highly

248 ave mapped ascending and descending axons to the previously described scaffold of longitudinal fiber

249 B. subtilis MifM and the previously described secretion monitor SecM in Esche

250 f striking "probe dependence" indicates that the previously described selectivity of the modulator do

251 h, but up to 100 nm in length, that resemble the previously described self-assembled Abeta protofibri

252 pe I IFNs via a pathway that did not involve the previously described sensors TLR9, DAI, RNA polymera

253 In early anaphase, the previously described separase inhibition of PP2A(Cdc

254 20alpha PS was composed of the previously described serotype 20 hexasaccharide repe

255 Furthermore, SID-5 acts differently than the previously described SID-1, SID-2, and SID-3 protein

256 Finally, we show that sid-5 is required for the previously described sid-1-independent transport of

257 important role of multiphoton reactions and the previously described side reaction for dark state re

258 e expression profiling, and in particular of the previously described signatures of cell signaling pa

259 tic buffer medium (pH=4.6) was compared with the previously described silver nanoparticle-based (AgNP

260 ion of highly purified HSC, and enriches for the previously described Slamf1(lo)CD34(-) lymphoid-bala

261 shared circuitry between dsx and a subset of the previously described SP-responsive fru(+)/ppk(+)-exp

262 Although we did not observe the previously described spine loss during ODP in either

263 Analogues of the previously described spiro[imidazo[1,5-c]thiazole-3,

264 Contrary to the previously described spliced peptides, which are pro

265 x and co-sediments in sucrose gradients with the previously described splicing factors Raa1 and Raa2.

266 e Src family inhibitor PP2, we observed that the previously described Src-dependent MT1-MMP phosphory

267 The previously described SRCRP2 peptide that was shown t

268 imates, this effect was strongly additive to the previously described stabilization of the prefusion

269 These findings challenge the previously described stealth properties of HBV.

270 tionship of intra-axonal TC10 synthesis with the previously described stimulus-induced translation of

271 we find that MscL is not only necessary for the previously described streptomycin-induced potassium

272 psule (CB-StC) and discuss its relation with the previously described striatal capsule in vertebrates

273 ging was performed for (68)Ga-aquibeprin and the previously described, structurally related c(RGDfK)

274 racemase apoprotein and used it, along with the previously described structures of lactate racemase

275 identified E4orf4 binding domain lies above the previously described substrate binding site and does

276 s and that these two enzymes can account for the previously described substrate breadth cleaved by si

277 lar, with only minor differences observed in the previously described surface variable regions, sugge

278 We applied the previously described synthetic attenuated virus engi

279 The technique is based on the previously described TAR cloning procedure developed

280 at lacks amino acids 87 to 106, a portion of the previously described TBK1-binding domain of the gamm

281 tinct cis-elements in the promoter of let-7, the previously described temporal regulatory element (TR

282 the RAD50 gene and thus are contiguous with the previously described TH2 locus control region (LCR)

283 Here we describe the genome of the previously described therapeutic B. cenocepacia podo

284 Loss-of-function mutations in components of the previously described thylakoid-localized Sec system,

285 by deletion of genes for both CafA and FimB, the previously described tip protein of the type 2 fimbr

286 The database is functionally expanded from the previously described Tomato Expression Database by i

287 esponse to iron and zinc, in accordance with the previously described transcriptional response of the

288 ansgenic mice more closely resemble LBs than the previously described transgenic mice (line M83) that

289 In contrast to the previously described transnitrilative cyanation of a

290 f conformationally restricted derivatives of the previously described TRPM8 antagonist N,N'-dibenzyl

291 film formation at a stage similar to that of the previously described two-component system BfiSR.

292 Collectively, these ILEs share features with the previously described type III protein secretion syst

293 This study supports the previously described typical CT appearance of COVID-

294 We studied the reliability of the previously described Ulcerative Colitis Endoscopic I

295 We thus explain the previously described unidirectional nature of lysine

296 These results help explain the previously described vacuolar acidification defect i

297 irection of these genes relative to those of the previously described VSH-1 16.3-kb gene operon indic

298 striking was the fact that BGHBV, ACHBV, and the previously described white sucker hepadnavirus did n

299 able to determine that StmPr3 contributes to the previously described Xps-mediated rounding and detac

300 The alarmone (p)ppGpp, but not the previously described YfgM interactors RcsB and PpiD,